119 related articles for article (PubMed ID: 15477304)
1. Pharmacogenomics and colorectal cancer.
Lenz HJ
Ann Oncol; 2004; 15 Suppl 4():iv173-7. PubMed ID: 15477304
[No Abstract] [Full Text] [Related]
2. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
[TBL] [Abstract][Full Text] [Related]
4. EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Spindler KG; Andersen RF; Jensen LH; Ploen J; Jakobsen A
Ann Oncol; 2010 Mar; 21(3):535-539. PubMed ID: 19850635
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
7. Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
Paré L; Marcuello E; Altés A; del Rio E; Sedano L; Barnadas A; Baiget M
Pharmacogenomics J; 2008 Oct; 8(5):315-20. PubMed ID: 17684476
[TBL] [Abstract][Full Text] [Related]
8. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Martinez-Balibrea E; Manzano JL; Martinez-Cardus A; Moran T; Cirauqui B; Catot S; Taron M; Abad A
Oncol Rep; 2007 Mar; 17(3):637-45. PubMed ID: 17273745
[TBL] [Abstract][Full Text] [Related]
9. [Oxaliplatin: combinations with thymidylate synthetase inhibitors: two consecutive phase II studies].
Martoni A; Mini E; Pinto C; Gentile A; Mazzei T
Tumori; 2001; 87(6):A25-6. PubMed ID: 11995701
[No Abstract] [Full Text] [Related]
10. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
Duran G; Cruz R; Simoes AR; Barros F; Giráldez JM; Bernárdez B; Anido U; Candamio S; López-López R; Carracedo Á; Lamas MJ
J Chemother; 2020 Oct; 32(6):310-322. PubMed ID: 32441565
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
Clamp AR; Schöffski P; Valle JW; Wilson RH; Marreaud S; Govaerts AS; Debois M; Lacombe D; Twelves C; Chick J; Jayson GC;
Cancer Chemother Pharmacol; 2008 Apr; 61(4):579-85. PubMed ID: 17520255
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Punt CJ
Ann Oncol; 2005 Jun; 16(6):845-6. PubMed ID: 15890668
[No Abstract] [Full Text] [Related]
15. Pharmacogenomics in colorectal cancer.
Lenz HJ
Semin Oncol; 2003 Aug; 30(4 Suppl 15):47-53. PubMed ID: 14523795
[TBL] [Abstract][Full Text] [Related]
16. Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
Di Francia R; De Lucia L; Di Paolo M; Di Martino S; Del Pup L; De Monaco A; Lleshi A; Berretta M
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4443-54. PubMed ID: 26636535
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
[TBL] [Abstract][Full Text] [Related]
19. Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer.
Schade H; Davis L; Kabos P
Oncology (Williston Park); 2016 Nov; 30(11):992-4, 1000-1. PubMed ID: 27854101
[No Abstract] [Full Text] [Related]
20. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
Pander J; Wessels JAM; Gelderblom H; van der Straaten T; Punt CJA; Guchelaar HJ
Ann Oncol; 2011 May; 22(5):1147-1153. PubMed ID: 21048041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
